Table of contents
November 2002 Vol 2 No 11
In this issue
p805 | doi:10.1038/nrc944
Research Highlights
Cancer Genetics: It doesn't always take two
p807 | doi:10.1038/nrc932
Drug Resistance: Damage limitation
p808 | doi:10.1038/nrc931
Angiogenesis: Multi-tasking
p808 | doi:10.1038/nrc937
Tumorigenesis: Converging paths
p809 | doi:10.1038/nrc940
News in Brief
Tumour suppressors | Prostate cancer | Angiogenesis | Apoptosis
p809 | doi:10.1038/nrc942
Tumorigenesis: Clockwork
p810 | doi:10.1038/nrc933
Telomerase: ALTernative pathways?
p810 | doi:10.1038/nrc935
Cell cycle: Divide and rule
p811 | doi:10.1038/nrc934
Oncogenesis: MYC reduces stress
p812 | doi:10.1038/nrc936
Trial Watch
SMART? Time will tell | Smokers wanted
p812 | doi:10.1038/nrc941
Tumour Immunology: Disarming defences
p813 | doi:10.1038/nrc938
Breast Cancer: Filling the hole
p813 | doi:10.1038/nrc939
In the news
Gene therapy resumes
p813 | doi:10.1038/nrc943
Focus on: Stem Cells
Reviews
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Shahin Rafii, David Lyden, Robert Benezra, Koichi Hattori & Beate Heissig
p826 | doi:10.1038/nrc925
Reviews
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Shahin Rafii, David Lyden, Robert Benezra, Koichi Hattori & Beate Heissig
p826 | doi:10.1038/nrc925
Centrosome aberrations: cause or consequence of cancer progression?
Erich A. Nigg
p815 | doi:10.1038/nrc924
The pathogenesis of pituitary tumours
Sylvia L. Asa & Shereen Ezzat
p836 | doi:10.1038/nrc926
New aspects of natural-killer-cell surveillance and therapy of cancer
Mark J. Smyth, Yoshihiro Hayakawa, Kazuyoshi Takeda & Hideo Yagita
p850 | doi:10.1038/nrc928
Cachexia in cancer patients
Michael J. Tisdale
p862 | doi:10.1038/nrc927
Perspectives
Science and society
Quality of life: a new perspective for cancer patients
Lesley Fallowfield
p873 | doi:10.1038/nrc930
Opinion
Telomere maintenance and cancer — look, no telomerase
Axel A. Neumann & Roger R. Reddel
p879 | doi:10.1038/nrc929

